<DOC>
	<DOCNO>NCT01452542</DOCNO>
	<brief_summary>The primary objective pilot study determine within-subject pharmacokinetic ( PK ) variability relative bioavailability single oral 150-mg dos eliglustat administer Phase 3 formulation ( 3x50-mg capsule ) common blend propose commercial formulation ( 1x150-mg capsule ) healthy adult subject , use plan support design subsequent bioequivalence study .</brief_summary>
	<brief_title>A Phase I Study Pharmacokinetic Variability Relative Bioavailability Phase 3 Common Blend Formulations Eliglustat Healthy Adult Subjects</brief_title>
	<detailed_description>This single-site , single-dose , randomize , open-label , two-treatment , two-sequence , four-period replicate crossover study healthy adult subject . The study comprise screen period , four treatment period 7-day washout dose period , safety follow-up visit .</detailed_description>
	<mesh_term>Eliglustat</mesh_term>
	<criteria>The subject willing able provide sign informed consent . The subject male female good general health 18 45 year age , inclusive . The subject body weight 50 100 kg ( 110 220 lb ) body mass index ( BMI ) ≤32 kg/m2 screening . The subject 's physical examination , laboratory , vital sign , ECG test result within normal limit screen Day 3 , abnormal , consider clinically significant opinion Investigator . The subject nonsmoker least 6 month prior time provide informed consent , willing able abstain smoking ( use form nicotine ) completion safety followup visit . The subject use drug abuse least 6 month prior Day 1 willing able abstain use drug abuse completion safety followup visit . The subject willing able abstain alcohol 48 hour prior first dose study drug completion safety followup visit . The subject willing able abstain grapefruit star fruit product 72 hour prior first dose study drug completion safety followup visit . The subject , female childbearing potential , documented negative pregnancy test screen Day 1 , willing use medically accept form contraception ( define protocol ) screen 30 day last dose study drug . A woman childbearing potential define female amenorrheic least 2 year undergone hysterectomy surgical sterilization . The subject classify CYP2D6 poor metabolizer ( indeterminate metabolizer neither allele know active ) CYP2D6 ultrarapid metabolizer ( indeterminate metabolizer one allele know correspond ultrarapid metabolism ) base result CYP2D6 genotyping perform screen . ( Note : Prior CYP2D6 genotyping result may use purpose determine study eligibility copy laboratory report available genotyping result interpret classification system use study reference laboratory . ) The subject digestive disorder , include malabsorption , gastroenteritis , pancreatitis , gastroesophageal reflux disease , inflammatory bowel disease ( include Crohn 's disease ) , digestive disorder , opinion Investigator , may affect oral bioavailability ( e.g. , clinically significant constipation , diverticulitis , irritable bowel syndrome ) . The subject GI surgical procedure might affect drug transit time , ( e.g. , cholecystectomy , GI bypass surgery , partial total gastrectomy , small bowel resection ) . The subject following : Clinically significant coronary artery disease include history myocardial infarction ongoing sign symptom consistent cardiac ischemia heart failure ; clinically significant arrhythmias conduction defect 2nd 3rd degree AV block , complete bundle branch block , prolong QTc interval ( e.g. , repeated demonstration QTc interval ≥450 msec ) , sustain ventricular tachycardia . The subject clinically significant organic disease , include cardiovascular , renal , hepatic , GI , pulmonary , neurologic , endocrine , metabolic , psychiatric disease , medical condition , serious intercurrent illness , extenuate circumstance , opinion Investigator , preclude participation trial . The subject receive treatment inducer CYP3A4 within 30 day prior first dose study drug . The subject receive treatment inhibitor CYP3A4 CYP2D6 within 30 day prior first dose study drug . The subject receive immunization within 30 day prior first dose study drug . The subject receive investigational product within 60 day prior first dose study drug plan receive investigational product time course study . The subject receive prescription nonprescription medication ( exception nonprescriptionstrength ibuprofen acetaminophen , topical nonsteroidal preparation , topical hydrocortisone ( 1 % strength ) ) dietary herbal supplement within 30 day 5 halflives ( whichever longer ) prior first dose study drug , without approval Investigator Sponsor . The subject history drug allergy clinically significant opinion Investigator ( e.g. , significant rash hive ) . The subject screening laboratory test result upper limit normal follow liver function test : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gamma glutamyltransferase ( GGT ) , total bilirubin . The subject test positive human immunodeficiency virus ( HIV ) antibody , hepatitis C antibody , hepatitis B surface antigen screening . The subject test positive urine drug abuse , urine alcohol , urine cotinine screening . The subject donate blood blood product within 30 day prior provide inform consent . The subject 's schedule travel plan prevent completion require visit . The subject schedule inpatient hospitalization , include elective surgery ( inpatient outpatient ) , study . The subject history cancer , exception basal cell carcinoma . The subject , female , pregnant lactating . The subject , opinion Investigator , unable adhere requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Genz-112638</keyword>
</DOC>